Measuring Financial Toxicity After Cancer Diagnosis and Treatment
Available instruments may not be capable of ascertaining all relevant domains
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1549 results
FDA Approves Dalteparin Sodium for Venous Thromboembolism in Paediatric Patients
Approval is based on evidence from two clinical trials in paediatric patients with or without cancer
Deep Learning Model’s Potential to Increase the Accuracy of Lung Cancer Screening
Automated prediction of malignancy risk of pulmonary nodules in chest CT scan
Rendering the Tumour Microenvironment More Sensitive to PD-1 Blockade
Results of the TONIC trial
FDA Approves Venetoclax for CLL and SLL
Approval is based on results from the CLL14 study
FDA Approves Avelumab Plus Axitinib for Renal Cell Carcinoma
Approval is based on results from the JAVELIN Renal 101 study
Next Generation Profiling of the Cancer Cell Line Encyclopedia
Acceleration of cancer research by use of model cancer cell lines
How to Improve Access to Expertise in Cancer Imaging
Practical steps to improve situation in the context of changing landscape of cancer imaging
FDA Approves Ramucirumab for Hepatocellular Carcinoma
Approval is based on results from the REACH‑2 study
EMA Recommends Granting a Marketing Authorisation for New Biosimilar Pegfilgrastim
Grasustek received a positive opinion for prophylaxis against neutropenia in adult patients treated with cytotoxic chemotherapy
FDA Approves Ado-trastuzumab Emtansine for Early Breast Cancer
It is indicated in the adjuvant treatment of patients with HER2-positive tumours who have residual invasive disease after pre-operative systemic treatment
EMA is Updating the Prescribing Information for Lapatinib
Re-analysis of data on use of breast cancer medicine lapatinib following treatment with trastuzumab